NVAX
NOVAVAX INCPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 26 ▲ Novavax reported strong financial results for Q4 and full year 2025,…
- Apr 27 Trial readout: T-90d Trial Readout: CIC Vaccine Co-formulated tNIV2 , SAR…
- Oct 16 ▼ Shah Capital Management filed Amendment No. 8 to its Schedule 13D, r…
- Nov 5 ▲ Earnings: NVAX Q3 2026 Earnings: EPS $-0.19 (+44.6% vs est)
- Nov 5 ▲ Novavax reported Q3 2026 total revenue of $68M, a 3% decline from $7…
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells since Mar 2. Recent filings are awards, exercises and tax withholding.
- InstitutionsMIXED
Q3 2026: 22 added (1 new), 18 trimmed or exited. Largest new: Hrt Financial $27.9M.
- AnalystsBULLISH
10 of 15 rate it Buy or better. Median target $16.00 (+99%).
- Short sellersSTEADY
Short interest −2.1% to 46.33M shares. 7.6 days to cover, ≈28.1% of shares.
- TrendDOWNTREND
23% below its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 3.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| HRT FINANCIAL LP | NEW | $27.9M |
| JUPITER ASSET MANAGEMENT LTD | DOUBLED | $26.7M |
| Invesco Ltd. | DOUBLED | $16.0M |
| UBS Group AG | TRIM | $14.7M |
| FEDERATED HERMES, INC. | ADD | $11.5M |
| Jump Financial, LLC | DOUBLED | $9.8M |
| FMR LLC | ADD | $9.4M |
| BARCLAYS PLC | DOUBLED | $8.3M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
15 analystsPrice is inside the target range. Median implies +99%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 6, 2026 | B. Riley Securities REITERATE | Buy |
| Oct 15, 2026 | Citigroup MAINTAIN | Sell |
| Jun 11, 2026 | BTIG REITERATE | Buy |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Alton Gregg H Director Jun 20, 2026 | EXERCISE | 18,880 sh |
MOTT DAVID M Director Jun 20, 2026 | EXERCISE | 18,880 sh |
MCGLYNN MARGARET G Director Jun 20, 2026 | EXERCISE | 18,880 sh |
DOUGLAS RICHARD Director Jun 20, 2026 | EXERCISE | 18,880 sh |
King Rachel K. Director Jun 20, 2026 | EXERCISE | 18,880 sh |
Rodgers Richard J Director Jun 20, 2026 | EXERCISE | 18,880 sh |
Newton Charles W. Director Jun 18, 2026 | AWARD | 21,270 sh |
Shiver John W. Director Jun 18, 2026 | AWARD | 21,270 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | -$0.35 | -$0.45–-$0.24 | -14.0% | $35.8M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
9 filings · 3 bullish · 1 bearish · 5 neutral- NEUTRAL SC 13GNov 10, 2026
State Street Corporation filed a Schedule 13G disclosing a passive 5.4% beneficial ownership stake…
This is a routine passive stake disclosure by a large index fund manager. No change in investment thesis. Monitor for any future 13D conversion or significant position changes in subsequent filings.
- BULLISH 8-KNov 5, 2026
Novavax reported Q3 2026 total revenue of $68M, a 3% decline from $70M in Q3 2025, and a GAAP net…
The $125M milestone from Sanofi's Phase 3 CIC trial initiation is already earned and recognized in Q4 2026, providing a significant cash boost. The raised revenue guidance signals confidence in the…
- BULLISH 8-KOct 29, 2026
Novavax announced that Sanofi dosed the fifth patient in its Phase 3 influenza-COVID-19…
The $125M milestone provides near-term cash visibility for Novavax, which has a $1.7B market cap. Monitor Sanofi's Phase 3 trial progress and the manufacturing tech transfer milestone (mid-2027) as…
- NEUTRAL SC 13GOct 16, 2026
Shah Capital Management, a North Carolina-based investment adviser, filed a Schedule 13G…
Monitor for any subsequent conversion to a Schedule 13D, which would signal activist intent. The 6.39% stake is notable but passive, so near-term catalyst is limited unless Shah Capital escalates.
All NVAX filing & press-release reports (9)
- SC 13G reportNov 10, 2026
- 8-K reportNov 5, 2026
- 8-K reportOct 29, 2026
- SC 13G reportOct 16, 2026
- SC 13D/A reportOct 16, 2026
- 8-K reportAug 6, 2026
- 8-K reportMay 6, 2026
- DEFA14A reportApr 27, 2026
- 8-K reportFeb 26, 2026